Novavax Statistics
Total Valuation
Novavax has a market cap or net worth of $1.39 billion. The enterprise value is $746.30 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Novavax has 160.18 million shares outstanding. The number of shares has increased by 59.45% in one year.
| Current Share Class | 160.18M |
| Shares Outstanding | 160.18M |
| Shares Change (YoY) | +59.45% |
| Shares Change (QoQ) | -3.50% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 52.82% |
| Float | 143.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.41 |
| Forward PS | 3.24 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.93
| Current Ratio | 0.93 |
| Quick Ratio | 0.89 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.46 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.76% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $573,683 |
| Profits Per Employee | -$184,613 |
| Employee Count | 1,543 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 19.68 |
Taxes
In the past 12 months, Novavax has paid $5.12 million in taxes.
| Income Tax | 5.12M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +66.35% in the last 52 weeks. The beta is 2.04, so Novavax's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | +66.35% |
| 50-Day Moving Average | 9.21 |
| 200-Day Moving Average | 10.51 |
| Relative Strength Index (RSI) | 46.62 |
| Average Volume (20 Days) | 3,765,704 |
Short Selling Information
The latest short interest is 39.78 million, so 24.84% of the outstanding shares have been sold short.
| Short Interest | 39.78M |
| Short Previous Month | 41.51M |
| Short % of Shares Out | 24.84% |
| Short % of Float | 27.75% |
| Short Ratio (days to cover) | 7.26 |
Income Statement
In the last 12 months, Novavax had revenue of $885.19 million and -$284.86 million in losses. Loss per share was -$1.99.
| Revenue | 885.19M |
| Gross Profit | 115.46M |
| Operating Income | -290.02M |
| Pretax Income | -288.88M |
| Net Income | -284.86M |
| EBITDA | -243.25M |
| EBIT | -290.02M |
| Loss Per Share | -$1.99 |
Full Income StatementBalance Sheet
The company has $909.53 million in cash and $262.23 million in debt, giving a net cash position of $647.31 million or $4.04 per share.
| Cash & Cash Equivalents | 909.53M |
| Total Debt | 262.23M |
| Net Cash | 647.31M |
| Net Cash Per Share | $4.04 |
| Equity (Book Value) | -526.44M |
| Book Value Per Share | -3.29 |
| Working Capital | -77.32M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$90.88 million and capital expenditures -$19.96 million, giving a free cash flow of -$110.85 million.
| Operating Cash Flow | -90.88M |
| Capital Expenditures | -19.96M |
| Free Cash Flow | -110.85M |
| FCF Per Share | -$0.69 |
Full Cash Flow StatementMargins
Gross margin is 13.04%, with operating and profit margins of -32.76% and -32.18%.
| Gross Margin | 13.04% |
| Operating Margin | -32.76% |
| Pretax Margin | -31.60% |
| Profit Margin | -32.18% |
| EBITDA Margin | -27.48% |
| EBIT Margin | -32.76% |
| FCF Margin | n/a |
Dividends & Yields
Novavax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -59.45% |
| Shareholder Yield | -59.45% |
| Earnings Yield | -20.44% |
| FCF Yield | -7.95% |
Analyst Forecast
The average price target for Novavax is $17.83, which is 104.94% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.83 |
| Price Target Difference | 104.94% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | -7.62% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 10, 2019. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | May 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
Novavax has an Altman Z-Score of -3.81 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.81 |
| Piotroski F-Score | 3 |